识别可能减缓轻度认知障碍的老年人认知衰退进展的运动干预措施:范围审查
Kerstin Castro1,2, Jo Ann M Bamdas3, Maria D Ortega4
1Medical School, Edward Via College of Osteopathic Medicine, Spartanburg, USA.
Cureus
|April 21, 2025
概括
定期炼,包括阻力训练和联合方式,可以显著减缓轻度认知障碍 (MCI) 的老年人认知能力下降. 这种方法为改善认知功能的药理干预提供了一个有希望的替代方案.
科学领域:
- 老年学和认知神经科学
- 运动生理学和公共卫生
背景情况:
- 轻度认知障碍 (MCI) 是正常衰老和痴呆之间的过渡阶段,其特点是认知缺陷不会显著影响日常生活.
- 有证据表明,运动干预可以缓解认知衰退,但美国的研究是有限的,可能是因为专注于药物治疗.
- 确定有效的运动策略对于管理老龄化人口中MCI至关重要.
研究的目的:
- 进行随机对照试验 (RCT) 的范围审查,调查MCI老年人的运动干预措施.
- 为了确定特定的运动类型和认知措施,与缓慢的认知进展在这个人口.
- 评估不同运动方式在改善老年人认知功能的有效性.
主要方法:
- 根据PRISMA-ScR指南进行了范围审查,搜索了五个主要数据库 (PubMed,GALE,Wiley,EBSCOHost,OVID).
- 搜索重点集中在2022年9月至2023年2月期间进行的检查运动干预措施和患有MCI的老年人认知衰退的RCT上.
- 分析了10项涉及1075名参与者的国际RCT (668名参与者分别属于干预组和对照组).
主要成果:
- 与对照组相比,联合炼模式对全球认知功能有更显著的益处.
- 阻力训练成为患有MCI的老年人特别有前途的干预措施.
- 审查确定了国际研究,强调需要更多的美国研究.
结论:
- 运动干预措施,特别是联合方式和抵抗训练,有效减缓患有MCI的老年人的认知衰退.
- 应考虑像运动这样的非药理学方法来管理MCI.
- 需要进一步的研究,特别是在美国,以探索运动对老龄人口认知健康的作用.
相关概念视频
01:30Cognitive Development During Adulthood
23
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
23
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
01:26Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
01:24Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148